Neuraxpharm seeks potential acquisitions to grow in and outside Europe
Neuraxpharm busca potenciales adquisiciones para crecer dentro y fuera de Europa
Intel ID : 323261
|
||||
| Intel ID | 323261 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Neuraxpharm
(31 Dec 2021) |
Revenue: EUR 56,11m EBITDA: EUR 11,76m Net Debt: EUR 53,05m People: 86 |
||
| Date |
 |
||
| Country | |
||
| Geography |  |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Private Equity (Buyer)
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Mergers & Acquisitions
| Date | Target | Country | Buyer | Seller | VALUE (EURm) | Subsector | |||
|
|
|
|
|
|
|
|
 |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.